BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today ...

Teachers in Washington state’s Peninsula school district seeking critical feedback on their instruction have a new tool to ...

Officials and experts in Argentina are scrambling to figure out if their country is the source of a deadly hantavirus outbreak that has gripped an Atlantic cruise. Argentina is consistently ...

JavaScript DOM manipulation is the backbone of creating dynamic, interactive web pages. From selecting elements to handling events and fetching data, mastering these skills transforms static HTML into ...

The illness suspected of causing an outbreak aboard a cruise ship is mainly spread by contact with rodents or their urine, ...

In the annual management reports of fund performance, several Vanguard ETFs attribute returns lagging benchmarks in part to ...

Our ‘In Focus’ campaign this month explores how younger generations are reshaping the advice landscape, from where they turn ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the therapy for transthyretin amyloid ...

Treatments have evolved for transthyretin amyloid cardiomyopathy (ATTR-CM), which occurs when a protein called transthyretin changes shape and builds up in the heart. Instead of simply addressing ...

In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...